Organization
Beijing Friendship Hospital, Beijing, China
3 abstracts
Abstract
Impact of time-of-day infusion of camrelizumab combined with chemotherapy on efficacy in advanced malignant tumors.Org: Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China, Guangdong Second Provincial General Hospital, Guangzhou, China, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, Beijing Friendship Hospital, Beijing, China,
Abstract
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Science and Peking Union Medical College,
Abstract
Efficacy and safety of time-of-day infusion of pemetrexed plus platinum and paclitaxel plus platinum for patients with advanced non-small cell lung cancer: A retrospective study.Org: Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China, Guangdong Second Provincial General Hospital, Guangzhou, China, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, Beijing Friendship Hospital, Beijing, China,